

August 24, 2015



AxoGen, Inc. Expands Presence at the American Society for Surgery of the Hand (ASSH) 2015

Sponsoring Interactive Panel Discussion with Leading Surgeons on the Value of Nerve Repair Technologies in Today's Practices

ALACHUA, FL – August 24, 2015– AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the expansion of their presence at this year's American Society for Surgery of the Hand (ASSH) 2015 Meeting, taking place September 10-12 in Seattle, Washington.

AxoGen, Inc. is sponsoring an interactive panel discussion entitled The Value of Nerve Repair Technologies in Your Practice on Friday, September 11 from 7:00-8:00am. The panel is comprised of leading nerve repair practitioners, including Peter Evans, MD PhD FRCS, Cleveland Clinic, Cleveland OH, Dean Sotereanos, MD, University of Pittsburgh Center, Pittsburgh PA, Bauback Safa, MD MBA FACS, The Buncke Clinic, San Francisco, CA, and Joaquim Casañas, MD, Teknon Medical Center, Barcelona, Spain. The panel will focus on the value of nerve repair technologies in today's nerve repair practices and will discuss current clinical data, evidence based repair algorithms, case planning, time saving approaches, repair optimization and clinical cases with participation from those in attendance.

AxoGen products will be discussed and demonstrated in scientific presentations, panel discussions and in educational programs during the conference. In addition, Karen Zaderej, AxoGen's President and CEO, is an invited speaker at the Women in Hand Surgery event.

"AxoGen is committed to providing access to the latest innovative techniques in peripheral nerve repair. Our technologies play a key role in providing surgeons with solutions for many of their standard, as well as challenging nerve injuries. These educational programs help to provide surgeons with the latest information on repair techniques that can be incorporated into the surgeon's daily practice", says Erick DeVinney, AxoGen's Vice President of Clinical and Translational Sciences.

In addition to sponsoring the educational forums, AxoGen will be exhibiting its full portfolio of nerve repair products at Booth 629 at the ASSH meeting.

About this Event

ASSH Industry Forum 18: The Value of Nerve Repair Technologies in Your Practice
Friday, September 11; 7:00 - 8:00 AM PST

Room 609, Washington State Convention Center

Panelists: Peter Evans, MD PhD FRCSC, Cleveland Clinic, Cleveland OH, Dean Sotereanos, MD, University of Pittsburgh Center, Pittsburgh PA, Bauback Safa, MD MBA FACS, The Buncke Clinic, San Francisco, CA, and Joaquim Casañas, MD, Teknon Medical Center, Barcelona, Spain

About AxoGen, Inc.

AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen's portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix ("ECM") coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, and are distributed worldwide exclusively by AxoGen. AxoGen maintains its corporate offices in Alachua, Florida and is the parent of its wholly owned operating subsidiary, AxoGen Corporation.

For more information about AxoGen or to sign up for our news alerts, please visit www.AxoGenInc.com.

Cautionary Statements Concerning Forward-Looking Statements

This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our 2015 revenue estimate, product development, product potential, financial performance, sales growth, product adoption, market awareness of our products, data validation, our visibility at and sponsorship of conferences and educational events. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

AxoGen, Inc.

Gregory Freitag, Chief Financial Officer & General Counsel

386.462.6856

InvestorRelations@AxoGenInc.com

EVC Group

Michael Polyviou/Doug Sherk – Investor Relations

212.850.6020/415.652.9100

mpolyviou@evcgroup.com; dsherk@evcgroup.com